Cardiac Pathways' strategy is to develop solutions for the most difficult cardiac rhythm problems, those for which even palliative treatments are limited. Armed with promising advanced technology, the company was one of the last through the 1996 medical device IPO window but since then has been paying the price for being slow to market. With FDA approval finally in hand, along with new management and additional financing obtained at a premium cost, Cardiac Pathways hopes to sustain itself long enough to finally take advantage of its technological lead by creating a new market treating patients who have few other options.
by Stephen Levin
You're a senior health care executive approached for the first time with an opportunity to become a president and CEO. That's the good news. Here's the bad news: you'll be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
